2Kim J, Choi C, Slain K, et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population the Korean Health and Genome Study. Psychiatry Clin Neurosci,2005,59:350-353.
3Berger K,Luedemann J,Trenkwalder C,et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med,2004,164:196-202.
4Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome : diagnostic criteria, special considerations, and epidemi ology. A report from the restless legs syndrome diagnosis and epldemiology workshop at the National Institutes of Health. Sleep Med,2003, 4: 101-119.
5Stiasny-Kolster K, Benes H ,Peglau I, et al. Effective cabergo line treatment in idiopathic restless legs syndrome. Neurology,2004,63:2272-2279.
6Partinen M, Hirvonen K,Jama L,et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-The PRELUDE study. Sleep Med, 2006,7 : 407-417.
7Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology, 2006,67:1034-1039.
8Trenkwalder C,Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome:result from the TREAT RLS 1 study, a 12 week, randomized, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry, 2004,75 : 92-97.
9Adler CH, Hauser RA,Sethi K, et al, Ropinirole for restless legs syndrome:a placebo-controlled crossover trial. Neurology,2004,62 : 1405-1407.
10Bliwise DL, Freeman A, Ingrain CD, et al. Randomized, double blind, placebo-controlled short term trial of ropinirole in restless legs syndrome. Sleep Med, 2005,6 : 141-147.
